The Medicines Patent Pool participated in AIDS 2024, the 25th International AIDS Conference in Munich, Germany and virtually from 22-26 July, as well as the pre-conference on 20 and 21 July. MPP shared a booth (#904) with Unitaid in the exhibition area.
AIDS 2024 convened thousands of people living with, affected by and working on HIV to share knowledge, best practices and lessons learnt from the HIV response over the past 40 years, as well as from the responses to COVID-19, mpox and other public health threats.
AIDS 2024 in Munich, Germany, and virtually provided a powerful platform to strategically align around a unified and equitable response to the pandemic. It signaed to the world that the HIV response is united behind an evidence-based approach that puts people first.
MPP colleagues actively participated in a number of sessions:
Saturday, 20 July, 8:00 – 9:00 | Room 14a / Channel 9 The PrEP product introduction landscape Pre-conference session (session 1) Esteban Burrone, Director, Policy, Strategy and Market Access, speaking as a panellist More information
Monday, 22 July, 11:30 – 12:30 | Room 14a/Channel 9 Lessons learned from the DTG story MPP/Unitaid satellite session Esteban Burrone, Director, Policy, Strategy and Market Access, providing closing remarks More information
Tuesday, 23 July, 10:30 – 11:30 | Room 13b/Channel 7 The law, human rights and access to medicines Oral abstract session | Track F: Political science, laws, ethics, policies and human rights Mila Maistat, Senior Manager, Policy, Strategy and Market Access, providing introductory remarks More information
Wednesday, 24 July, 18:00 – 19:30 | Hall B0a/Channel 4 An action plan to accelerate bNAbs for peri- and post-natal prophylaxis (PNP) IAS, IAVI, Desmond Tutu Health Foundation satellite session Sébastien Morin, Senior Manager, Policy, Strategy and Market Access, speaking as a panellist More information
Friday, 26 July, 10:30 – 11:30 | Room 1/Channel 2 No retreat! No surrender! The urgency of aligning investments where they are needed the most in the global HIV response Symposium | Track E: Implementation science, economics, systems and synergies Lobna Gaayeb, Head of Scientific and Medical Affairs, moderating the session More information
Friday, 26 July, 12:00 – 13:00 | Room 13b/Channel 7 Taking Action on Long-Acting Injectable PrEP: Towards access and implementation Symposium | Track E: Implementation science, economics, systems and synergies Esteban Burrone, Director, Policy, Strategy and Market, moderating the session More information
MPP shared a booth (#904) with Unitaid in the exhibition area.
Tuesday, 23 July, 11:30 – 12:00 | AVAC’s Research Literacy Zone at the Global Village (booth HT0401) Process and considerations for generics licensing with MPP Session organised by AVAC in collaboration with CS Caucus of LA PrEP Coalition Sébastien Morin, Senior Manager, Policy, Strategy and Market Access, presenting
Tuesday, 23 July, 14:00 – 14:50 | PLHIV Networking Zone at the Global Village #BetterMeds4Kids – Children’s Access to Life-Saving HIV Treatment Session organised by GNP+ and PATA Sébastien Morin, Senior Manager, Policy, Strategy and Market Access, presenting
Wednesday, 24 July, 9:45 – 10:45 | Booth of France in the Exhibition Area (#804) Accès équitable aux traitements et innovations contre le VIH : regards croisés sur les leçons apprises et défis à venir Session organised by France, moderated by Anne-Claire Amprou, French Ambassador for Global Health Esteban Burrone, Director, Policy, Strategy and Market, speaking
Wednesday, 24 July, 11:30 – 12:30 | Booth of MPP and Unitaid in the Exhibition Area (#904) Direct from the Source: The DTG Film Story Session organised by MPP – download flyer > Step behind the lens and experience the making of the “I am part of the DTG story” film. Meet and converse with the community heroes who shared their powerful stories during the cinema premiere at the World Health Assembly. Join us at the MPP booth for this enlightening session Watch the recording: YouTube live
Wednesday, 24 July, 13:15 – 14:00 | Booth of MPP and Unitaid in the Exhibition Area (#904) #BetterMeds4Kids: Accelerating access to better HIV medicines for children Session organised by MPP and partners of the Global Accelerator for Paediatric Formulations (GAP-f) WHO network – download flyer > Children are one of the most vulnerable yet neglected populations in terms of access to optimal medicines in adapted formulations. Consequently, paediatric therapies often remain limited and sub-optimal. Hear from partners of the Global Accelerator for Paediatric Formulations (GAP-f) WHO network, of which MPP is a founding member, as they share their experiences in addressing innovation and access challenges in developing and improving access to HIV medicines for children. Watch the recording: YouTube live
Thursday, 25 July, 11:00 – 12:00 | Booth of MPP and Unitaid in the Exhibition Area (#904) NAVIGATING LONG-ACTING THERAPEUTICS: LAPaL, a database at the Intersection of Innovation and Access Session organised by MPP – download flyer > LAPaL is the only online open access tool dedicated to supporting access to long-acting therapeutics. It not only provides patent and licensing information about key long-acting technologies and compounds, but also captures clinical development, regulatory filing information of selected treatment and prevention medicines. LAPaL aim is to provide reliable information and support innovation in the long-acting therapeutics while fostering access. Join this hands-on session to discover it! If possible, come with your computer/tablet to get the full experience!
Département communication, presse et médias
Le Medicines Patent Pool (MPP) est une organisation de santé publique soutenue par les Nations Unies, dont la mission est d’améliorer l’accès à des médicaments essentiels dans les pays à revenu faible et intermédiaire, et de faciliter la mise au point de tels médicaments. Au travers de son modèle économique innovant, le MPP collabore avec la société civile, les gouvernements, des organisations internationales, l’industrie, des groupes de patients et d’autres acteurs afin d’établir des priorités, de délivrer des licences sur les médicaments indispensables et de centraliser les actifs de propriété intellectuelle pour faciliter la fabrication de médicaments génériques et l’élaboration de nouvelles formulations.
À ce jour, le MPP a signé des accords avec 22 titulaires de brevets pour 13 antirétroviraux contre le VIH, une plateforme technologique sur le VIH, trois antiviraux à action directe contre l’hépatite C, un traitement contre la tuberculose, un traitement contre le cancer, quatre technologies à action prolongée, un traitement de l’hémorragie du post-partum, trois traitements antiviraux oraux contre la COVID-19 et 16 technologies liées à la COVID-19.
MPP a été fondé par Unitaid, qui continue d’être le principal bailleur de fonds de MPP. Le travail de MPP sur l’accès aux médicaments essentiels est également financé par l’Agence suisse pour le développement et la coopération (SDC), le gouvernement du Canada, l’Organisation mondiale de la propriété intellectuelle (OMPI) et le gouvernement de la Flandre. Les activités de MPP dans le cadre de la COVID-19 sont entreprises avec le soutien financier du gouvernement japonais, du ministère français de l’Europe et des Affaires étrangères, de l’Agence allemande de coopération internationale et de la SDC.